Viloxazine (Qelbree): A Faster Strattera?

On April 2, 2021, viloxazine, brand name Qelbree, received FDA approval for the treatment of ADHD in children and adolescents ages 6-17 years old. The latest issue of The Carlat Child Psychiatry Report includes a News of Note covering this newly approved medication for ADHD. In this podcast, we discuss the advantages and disadvantages of viloxazine for children and adolescents with ADHD.

https://www.thecarlatreport.com/podcast/viloxazine-qelbree-a-faster-strattera-2/

 

Author
Joshua Feder, M.D. Dr. Feder's Blog

You Might Also Enjoy...

Addressing Weight Stigma in Clinical Practice

Every patient and family you see is inescapably impacted by weight stigma or fat shaming and the damage from this bias can be lethal. In this podcast, Mara and I help your patients to shield themselves from weight stigma with healthier attitudes.

School Inclusion: What You Need to Know

When a school placement is a bad fit, medication and therapy are unlikely to make much difference. In this episode, we will help you understand and assist your patients to optimize their success in the least restrictive placement.